Self-Nanoemulsifying Formulation Improves Oral Bioavailability and Insulin Sensitizing Potency of Formononetin–Vitamin E Conjugate in Type 2 Diabetic Mice
Molecular Pharmaceutics · 2025
DOI: 10.1021/acs.molpharmaceut.4c00886 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Rakesh Kumar Dhritlahre und 5 weiteren Autor:innen. Beteiligte Einrichtung: Formulation Laboratory, Dietetics & Nutrition Technology Division, CSIR - Institute of Himalayan Bioresource Technology, Palampur, Himachal Pradesh 1…. Hauptthemen laut MEDLINE: Isoflavones, Biological Availability, Rats, Sprague-Dawley, Emulsions. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 101 Literaturangaben. Gefördert von: Council of Scientific and Industrial Research, India, University Grants Commission, Academy of Scientific and Innovative Research.
Abstract (Originalsprache)
The escalating incidence of obesity, diabetes, and insulin resistance has become a significant global health concern. In this study, we have developed a self-nanoemulsifying delivery system (SNEDS) of formononetin-vitamin E conjugate (VESylated-FMN) for improving its oral bioavailability and improving insulin sensitivity and glycemic control. The developed SNEDS were characterized using dynamic light scattering and transmission electron microscopy. Thereafter, the loading capacity, in vitro release, thermodynamic, and gastrointestinal stability of the developed formulation were evaluated. The safety and oral bioavailability of VESylated-FMN-SNEDS were assessed in Sprague-Dawley rats, whereas insulin-sensitizing potency was assessed in high-fat diet-induced type 2 diabetic mice. The VESylated-FMN-SNEDS quickly emulsified on dilution (droplet size ∼79.17 nm) and showed remarkable thermodynamic and gastrointestinal stability. The developed formulation demonstrated enhanced oral bioavailability (∼1.3-fold higher AUC0-t) of VESylated-FMN without liver and kidney injury. Consequently, VESylated-FMN-SNEDS significantly improves insulin sensitivity and glycemic control in HFD-fed mice compared to VESylated-FMN by upregulating the transcript level of insulin-sensitizing genes. Therefore, the SNEDS formulation could be an effective strategy to augment the oral bioavailability and insulin-sensitizing potency of VESylated-FMN.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Formulation Laboratory, Dietetics & Nutrition Technology Division, CSIR - Institute of Himalayan Bioresource Technology, Palampur, Himachal Pradesh 176061, India.
- Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, Uttar Pradesh 201002, India.
- Pharmacology and Toxicology Laboratory, Dietetics & Nutrition Technology Division, CSIR - Institute of Himalayan Bioresource Technology, Palampur, Himachal Pradesh 176061, India.
ORCID-Profile: Vikram Patial, Yogendra Padwad, Ankit Saneja
Förderung
- Council of Scientific and Industrial Research, India
- University Grants Commission
- Academy of Scientific and Innovative Research
Zitieren
APA
Dhritlahre, R. K., Thakur, N., Goel, A., Patial, V., Padwad, Y., & Saneja, A. (2025). Self-Nanoemulsifying Formulation Improves Oral Bioavailability and Insulin Sensitizing Potency of Formononetin–Vitamin E Conjugate in Type 2 Diabetic Mice. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c00886
Vancouver
Dhritlahre RK, Thakur N, Goel A, Patial V, Padwad Y, Saneja A. Self-Nanoemulsifying Formulation Improves Oral Bioavailability and Insulin Sensitizing Potency of Formononetin–Vitamin E Conjugate in Type 2 Diabetic Mice. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.4c00886
BibTeX
@article{Dhritlahre2025,
author = {Dhritlahre, Rakesh Kumar and Thakur, Navneet and Goel, Abhishek and Patial, Vikram and Padwad, Yogendra and Saneja, Ankit},
title = {Self-Nanoemulsifying Formulation Improves Oral Bioavailability and Insulin Sensitizing Potency of Formononetin–Vitamin E Conjugate in Type 2 Diabetic Mice},
journal = {Molecular Pharmaceutics},
year = {2025},
doi = {10.1021/acs.molpharmaceut.4c00886}
}
EUVIMED